VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

A treatment for
Stage IA/IB MF-CTCL that is clear

Artistic rendition of Stage IA/IB MF-CTCL. Not an actual patient.

*VALCHLOR (n=119) was assessed in a 12-month randomized, multicenter, observer-blinded, noninferiority study trial (N=260) vs Aquaphor®-based mechlorethamine HCl 0.02%. Primary endpoint: response by CAILS (Composite Assessment of Index Lesion Severity) score (combined scores for erythema, scaling, plaque elevation, and surface area). CAILS ORR: 60% (PR 45% + CR 14%). VALCHLOR noninferiority demonstrated by the rate ratio of 1.24 (95% CI, 0.98, 1.58). ORR (overall response rate) = PR (partial response) + CR (complete response, defined as a score of 0).1,2

VALCHLOR is the first and only FDA-approved
topical form of mechlorethamine1,3

VALCHLOR copay program
Eligible patients pay
no more than $10 $0 per
prescription fill